In the context of the regulatory relationship between ROR2 and Akt, studies have indicated that ROR2 can modulate Akt phosphorylation through activation or inhibition in different cancers, including melanoma, breast cancer, myeloma, and osteosarcoma [41–44]. The gene discussed is ROR2; the disease is plasma cell myeloma.